Eton Pharmaceuticals Inc (ETON)
$4.59
Performance
- $4.54$4.63$4.59
1.07%
Downside
Day's Volatility :1.92%
Upside
0.86%
- $3.03$5.81$4.59
33.99%
Downside
52 Weeks Volatility :47.85%
Upside
21.0%
Returns
| Period | Eton Pharmaceuticals Inc | |
|---|---|---|
3 Months | 27.15% | |
6 Months | 2.23% | |
1 Year | 1.55% | |
3 Years | 32.28% |
Highlights
Market Capitalization | 119.6M |
Book Value | $0.52 |
Earnings Per Share (EPS) | -0.26 |
Wall Street Target Price | 8.5 |
Profit Margin | -21.31% |
Operating Margin TTM | -32.35% |
Return On Assets TTM | -12.5% |
Return On Equity TTM | -44.3% |
Revenue TTM | 31.4M |
Revenue Per Share TTM | 1.22 |
Quarterly Revenue Growth YOY | -24.4% |
Gross Profit TTM | 14.3M |
EBITDA | -5.3M |
Diluted Eps TTM | -0.26 |
Quarterly Earnings Growth YOY | -0.13 |
EPS Estimate Current Year | -0.15 |
EPS Estimate Next Year | 0.26 |
EPS Estimate Current Quarter | -0.07 |
EPS Estimate Next Quarter | 0.02 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 85.19%
Technicals Summary
Sell
Neutral
Buy
Eton Pharmaceuticals Inc is currently in a neutral trading position according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Eton Pharmaceuticals Inc | 32.09% | 2.23% | 1.55% | 32.28% | 32.28% |
 Neurocrine Biosciences Inc. | -16.62% | -11.2% | 10.78% | 28.21% | 20.17% |
 Haleon Plc Spon Ads | 7.49% | 20.7% | 28.48% | 39.27% | 39.41% |
 Zoetis Inc. | 0.99% | 4.25% | 0.77% | -8.94% | 49.4% |
 Viatris Inc. | 2.73% | -5.35% | 16.7% | -20.4% | -28.58% |
 Catalent, Inc. | 0.82% | 7.17% | 22.57% | -57.2% | 16.16% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Eton Pharmaceuticals Inc | 120.67 | NA | NA | -0.15 | -0.44 | -0.12 | NA | 0.52 |
Neurocrine Biosciences Inc. | 36.51 | 36.51 | 0.28 | 4.57 | 0.16 | 0.12 | NA | 24.87 |
Haleon Plc Spon Ads | 33.19 | 33.19 | 1.45 | 0.39 | 0.07 | 0.04 | 0.02 | 1.82 |
Zoetis Inc. | 36.66 | 36.66 | 2.59 | 5.82 | 0.49 | 0.14 | 0.01 | 10.94 |
Viatris Inc. | 224.4 | NA | 0.07 | 2.67 | -0.03 | 0.03 | 0.04 | 16.36 |
Catalent, Inc. | 211.02 | NA | 2.9 | 0.2 | -0.25 | 0.0 | NA | 19.91 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Eton Pharmaceuticals Inc | Buy | $119.6M | 32.28% | 120.67 | -21.31% |
Neurocrine Biosciences Inc. | Buy | $12.4B | 20.17% | 36.51 | 16.0% |
Haleon Plc Spon Ads | Buy | $46.9B | 39.41% | 33.19 | 9.66% |
Zoetis Inc. | Buy | $84.9B | 49.4% | 36.66 | 26.29% |
Viatris Inc. | Hold | $13.5B | -28.58% | 224.4 | -4.24% |
Catalent, Inc. | Hold | $11.0B | 16.16% | 211.02 | -23.81% |
Institutional Holdings
Opaleye Management Inc
9.27%Vanguard Group Inc
3.98%Nantahala Capital Management, LLC
3.64%Westside Investment Management, Inc.
2.27%Acuitas Investments, LLC
2.24%Paradigm Capital Management, Inc.
1.16%
Company Information
eton pharmaceuticals, inc. is a deer park, illinois-based pharmaceutical company focused on developing and commercializing innovative pharmaceutical products utilizing the u.s. food and drug administration’s 505(b)(2) regulatory pathway. our mission is to advance healthcare through the introduction of innovative medicines that are affordable and available to all patients.
Organization | Eton Pharmaceuticals Inc |
Employees | 30 |
CEO | Mr. Sean E. Brynjelsen |
Industry | Health Technology |
Discover More
A Spac I Acquisition Corp
$4.59
-0.43%
Keyarch Acquisition Corp
$4.59
-0.43%
Connexa Sports Technologies Inc
$4.59
-0.43%
Us Value Etf
$4.59
-0.43%
First Wave Biopharma Inc
$4.59
-0.43%
Global X Msci Next Emerging
$4.59
-0.43%
Fat Projects Acquisition Corp
$4.59
-0.43%
Capital Link Global Fintech
$4.59
-0.43%
Applied Uv Inc
$4.59
-0.43%